Cure4Cancer Experts at ASCO 2026: Accelerating Equitable Clinical Trial Access Worldwide and New Milestones in Lung Cancer Care
Onco Daily; May 29, 2026
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2 in Chicago, showcased major clinical milestones and strategic global collaborations aimed at transforming cancer care worldwide.
Dr. Bob Li, Senior Vice President and Global Head of Medical Affairs, Oncology at AstraZeneca, participated in high-profile global forums during the meeting. Alongside ASCO Chief Medical Officer Dr. Julie Gralow, Dr. Li emphasized the role of global collaboration and real-world data in expanding equitable clinical trial access for diverse patient populations.
International clinical trials led in partnership by Dr. Yi-Long Wu and his team from the Guangdong Lung Cancer Institute showcased breakthrough advancements in targeted therapies for non-small cell lung cancer, specifically focusing on RET fusions and EGFR mutations.
These presentations underscore the intensifying integration of international research efforts to deliver more precise, targeted interventions for lung cancer patients globally.
